The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL10R and/or a human or chimeric (e.g., humanized) IL10, and methods of use thereof.

Described herein are protein-payload conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic and/or imaging agent moieties. In certain embodiments, provided are specific and efficient methods for producing protein-payload constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and Diels-Alder techniques. Antibody-drug conjugates and compositions which comprise glutaminyl-modified antibodies, Diels-Alder adducts, and reactive payloads and are provided.

The invention relates to water soluble .sup.18F-prosthetic groups and the synthesis and use of .sup.18F-labeled biological molecules containing the .sup.18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient.

The present application relates to a metal-nucleic acid nanoparticle which is a nanoparticle having a spherical structure formed by assembly of metal ions with nucleic acids via coordination. The preparation thereof is mixing a metal ion solution with a nucleic acid solution to obtain a mixture followed by vortex, heating, centrifugation, washing with water and resuspension to obtain the metal-nucleic acid nanoparticles.

There is provided a system for evaluating an ultraviolet-protection product to be applied to skin, including a light source generating an output beam and a spacer mountable to the light source for maintaining a fixed distance between the light source and the skin. The spacer includes a mounting bracket engageable with the light source and a frame mechanically connected to the mounting bracket and extending longitudinally outwardly from the mounting bracket, the frame comprising an outer periphery, an inner periphery and a skin-contacting portion, the inner periphery defining a hollow region therein, such that when the skin-contacting portion is engaged with the skin, the beam passes through the hollow region and interacts with the skin at an illumination plane to define an illuminated area confined within the hollow region, the ultraviolet-protection product remaining substantially unaffected in the illuminated area upon relative movement of the skin with respect to the frame.

A tracer detection device includes an enclosed body, and a plurality of tracer sensors, a battery, a memory, and a transmitter, each disposed within the enclosed body. The plurality of tracer sensors is configured to detect measurement values at a surface and underneath the surface of a gastrointestinal tract. The battery is configured to power the plurality of tracer sensors. The memory is configured to receive measurement values detected by the plurality of tracer sensors. The transmitter is configured to transmit measurement values detected by the plurality of tracer sensors to an external device after the enclosed body has passed through the gastrointestinal tract. The enclosed body includes a steering feature that ensures the enclosed body is oriented in an intended direction. The plurality of tracer sensors triggers release of a drug. The plurality of tracer sensors estimate distances to gastrointestinal walls for normalizing signals.

Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.

Provided are targeted nanoparticles. In certain embodiments, the targeted nanoparticles comprise a nanoparticle and a myeloid cell (MC) targeting moiety stably associated with the outer surface of the nanoparticle. According to some embodiments, the MC targeting moiety is an immunosuppressive myeloid cell (isMC) targeting moiety. In certain embodiments, the targeted nanoparticles further comprise a detectable label (e.g., an in vivo imaging agent), a drug, or both. Also provided are compositions comprising the targeted nanoparticles of the present disclosure. Methods of using the targeted nanoparticles to image MCs (e.g., isMCs) and/or to modulate and/or disrupt MCs (e.g., isMCs) are also provided.